Home
News
Expanded Access
…
Home
News
Expanded Access
Home
News
Expanded Access
…
Home
News
Expanded Access
Home
News
Expanded Access
News
Recent news on Salspera
FDA GRANTS FAST TRACK DESIGNATION TO SALSPERA'S SALTIKVA, AN INNOVATIVE IMMUNOTHERAPEUTIC APPROACH TO TREAT METASTATIC PANCREATIC CANCER
June 1, 2022
Salspera today announced the U.S. Food and Drug Administration (FDA) granted Fast Track...
FDA GRANTS ORPHAN DRUG DESIGNATION (ODD) TO SALSPERA'S SALTIKVA, AN INNOVATIVE IMMUNOTHERAPEUTIC APPROACH TO TREAT METASTATIC PANCREATIC CANCER
May 23, 2022
Salspera today announced the U.S. Food and Drug Administration (FDA) granted Orphan Drug...
Salspera Announces Positive Topline Data in Phase 2 Trial of Saltikva in Metastatic Pancreatic Cancer
September 27, 2021
Oakdale, MN, September 27th, 2021 – Salspera, LLC, a clinical stage biotechnology developing...
More Posts
All Posts
×
Cookie Use
We use cookies to ensure a smooth browsing experience. By continuing we assume you accept the use of cookies.
Accept
Learn More